Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alzheimer Disease Assessment Scale: a subtest analysis.

R F Zec1, E S Landreth, S K Vicari

  • 1Department of Psychiatry, Southern Illinois University School of Medicine, Springfield 62794-9230.

Alzheimer Disease and Associated Disorders
|January 1, 1992
PubMed
Summary

The Alzheimer Disease Assessment Scale (ADAS) effectively measures dementia severity. Memory and language subtests detect early Alzheimer's disease (AD) changes, while orientation best tracks progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure.

ESMO open·2023
Same author

Probabilistically Perfect Cloning of Two Pure States: Geometric Approach.

Physical review letters·2016
Same author

Familial dyslexia: genetic and medical findings in eleven three-generation families.

Annals of dyslexia·2013
Same author

The safety and efficacy of gi endoscopy in patients with acute-leukemia - a review of 27 cases.

International journal of oncology·2011
Same author

Evidence-based guideline: Treatment of painful diabetic neuropathy [RETIRED]: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.

Neurology·2011
Same author

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.

Neurology·2008

Area of Science:

  • Neurology
  • Gerontology
  • Psychometrics

Background:

  • Alzheimer's disease (AD) poses a significant challenge in cognitive assessment.
  • The Alzheimer Disease Assessment Scale (ADAS) is a widely used tool for evaluating cognitive function in AD patients.
  • Understanding the sensitivity of ADAS subtests across different dementia severities is crucial for accurate diagnosis and monitoring.

Purpose of the Study:

  • To evaluate the performance of the Alzheimer Disease Assessment Scale (ADAS) across varying severity levels of dementia.
  • To identify which ADAS subtests are most sensitive to cognitive decline in Alzheimer's disease.
  • To determine the best indicators of dementia progression using the ADAS.

Main Methods:

  • Administered the ADAS Cognitive and Noncognitive subtests to 61 Alzheimer patients and control groups (52 elderly, 80 younger).

Related Experiment Videos

  • Categorized Alzheimer patients into severity levels (very mild, mild, moderate, severe) using Mini-Mental State Examination (MMSE) scores.
  • Performed statistical analyses to compare ADAS scores between patient and control groups and across dementia severity levels.

    • Main Results:

    • All 11 ADAS Cognitive subtests were significantly worse in mild, moderate, and severe dementia groups compared to elderly controls.
    • Memory and spontaneous language subtests showed early decline; praxis, commands, and naming were sensitive later in the disease course.
    • The Orientation subtest, ADAS Cognitive score, and ADAS Total score were the strongest indicators of dementia progression; Noncognitive subtests showed less progression.

    Conclusions:

    • The ADAS Cognitive subtests are sensitive to cognitive impairment in Alzheimer's disease across severity levels.
    • Specific subtests like memory and language are early indicators, while Orientation is a key indicator of overall progression.
    • ADAS subtest performance reflects the pattern of cognitive impairment in AD and potential psychometric properties of the scale.